Wits Commercial Enterprise South Africa

Wits researchers have developed a compound for the treatment of age-related diseases, such as cancer and cellular ageing. The compound occurs naturally in the body, and reduces the effects of telomerase activity in cells in a manner that prevents ageing of the cells. The compound, a protein fragment laminin receptor (LRP/LR), regulates telomerase activity in cells; effectively negating the impact of telomere shortening and thus cellular ageing. The targeting of the telomere-related diseases using protein fragments which are native to the body’s cells provides a therapeutic which is safer than existing solutions. The LRP/LR fragment is flexible and can be used for both therapeutic as well as non-therapeutic treatments such as cosmetic uses.

Intellectual Property Protection

Opportunity type

Technology Readiness Level